US · ATRA
Atara Biotherapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- South San Francisco, CA 94080
- Website
- atarabio.com
Price · as of 2024-12-31
$4.90
Market cap 39.08M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $138.16 | +2,719.59% |
| Intrinsic Value(DCF) | $2.76 | -43.67% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | $785.50 | ||||
| 2015 | $414.50 | ||||
| 2016 | $525.00 | ||||
| 2017 | $1,103.75 | ||||
| 2018 | $913.00 | ||||
| 2019 | $311.25 | ||||
| 2020 | $422.50 | ||||
| 2021 | $225.50 | ||||
| 2022 | $70.75 | $28.30 | $0.00 | $0.00 | $0.00 |
| 2023 | $19.05 | $7.62 | $0.00 | $0.00 | $4,869.09 |
| 2024 | $6.90 | $138.16 | $613,731.77 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Atara Biotherapeutics, Inc.'s (ATRA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $138.16
- Current price
- $4.90
- AI upside
- +2,719.59%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2.76
-43.67% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ATRA | Atara Biotherapeutics, In… | $4.90 | 39.08M | +2,720% | -44% | — | — | -0.60 | -0.53 | 0.40 | -0.70 | — | -0.53 | 83.71% | -64.71% | -66.23% | 86.92% | 88.27% | -62.20% | -0.45 | -18.08 | 0.48 | 0.33 | -0.25 | -8249.00% | 140402.00% | -6449.00% | -133.48% | -0.51 | 72.96% | 0.00% | 0.00% | 25.61% | -0.64 | -0.77 | 0.41 | -28.32 |
| CLNN | Clene Inc. | $5.23 | 48.62M | +633% | -65% | — | +3,976% | -0.81 | -3.60 | 93.13 | -1.20 | — | -3.60 | 79.53% | -9676.32% | -11520.47% | -1738.36% | -637.51% | -98.90% | -2.35 | -8.14 | 1.57 | 1.22 | -0.26 | -3987.00% | -4771.00% | -3003.00% | -67.00% | -2.07 | -411.12% | 0.00% | 0.00% | 0.00% | -1.22 | -1.90 | 118.53 | -17.65 |
| CNTX | Context Therapeutics Inc. | $2.25 | 206.73M | — | — | — | — | -1.75 | 0.49 | — | 1.59 | — | 0.49 | 0.00% | — | — | -49.89% | 3929.63% | -46.81% | 0.00 | — | 35.62 | 34.36 | 3.15 | -6933.00% | — | 3927.00% | -62.65% | -5.30 | 3849.40% | 0.00% | 0.00% | 170.46% | 1.58 | 1.62 | — | 8.62 |
| COYA | Coya Therapeutics, Inc. | $4.96 | 82.41M | +515% | -78% | — | +508% | -7.05 | 2.65 | 29.50 | -3.87 | -29.29 | 2.65 | -233.86% | -485.35% | -418.70% | -39.57% | -774.97% | -34.76% | 0.00 | — | 11.59 | 10.22 | 2.23 | 2405.00% | -4079.00% | -804.00% | -9.81% | -2.69 | -484.62% | 0.00% | 0.00% | 5.45% | -3.86 | -6.46 | 18.71 | 11.79 |
| CSBR | Champions Oncology, Inc. | $5.96 | 82.69M | +4,602% | -30% | -67% | +22% | 23.54 | 29.33 | 1.94 | 17.00 | — | 32.19 | 47.27% | 8.51% | 8.26% | 503.05% | 322.96% | 16.08% | 1.62 | 179.48 | 0.94 | 0.88 | -0.58 | -16111.00% | 1354.00% | -20034.00% | 6.32% | 0.31 | 466.31% | 0.00% | 0.00% | 7.68% | 22.07 | 15.29 | 1.88 | 1.07 |
| IFRX | InflaRx N.V. | $0.92 | 62.33M | +5,018% | -48% | — | — | -1.32 | 0.99 | 367.43 | -0.95 | — | 0.99 | -1900.76% | -31973.69% | -27784.96% | -56.18% | -78.66% | -46.95% | 0.01 | -2566.39 | 5.06 | 1.30 | 0.39 | 0.00% | 16279.00% | 2826.00% | -79.79% | -3.43 | -72.12% | 0.00% | 0.00% | 9.72% | -0.82 | -0.89 | 261.45 | -5.01 |
| MGNX | MacroGenics, Inc. | $1.99 | 125.88M | +1,648% | -54% | — | — | -2.12 | 1.22 | 0.96 | 0.38 | -0.35 | 1.22 | 91.71% | -74.54% | -45.14% | -49.85% | 242.04% | -23.91% | 0.32 | -99.17 | 3.92 | 3.71 | 2.53 | 61333.00% | 15937.00% | -987.00% | -50.71% | -1.23 | 157.77% | 0.00% | 0.00% | 55.15% | 0.20 | 0.31 | -0.15 | -5.76 |
| ORMP | Oramed Pharmaceuticals In… | $3.42 | 136.08M | +1,195% | — | — | — | -5.13 | 0.67 | — | 2.94 | — | 0.67 | 0.00% | — | — | -12.29% | -43.99% | -10.14% | 0.00 | -14.98 | 25.19 | 24.97 | 3.63 | -43571.00% | -10000.00% | -2009.00% | -8.62% | -1.48 | -29.02% | 0.00% | 0.00% | 101.31% | 3.42 | 5.19 | — | 5.11 |
| OVID | Ovid Therapeutics Inc. | $1.63 | 116.08M | +1,596% | -87% | — | — | -1.39 | 0.54 | 65.14 | 0.03 | — | 0.54 | 100.00% | -10933.75% | -4670.14% | -33.88% | -444.08% | -22.38% | 0.22 | — | 5.32 | 5.04 | 0.20 | -5000.00% | 4439.00% | 2201.00% | -151.96% | -5.32 | -402.05% | 0.00% | 0.00% | 1.37% | 0.02 | 0.03 | -2.56 | -5.32 |
| STRO | Sutro Biopharma, Inc. | $20.47 | 174.27M | -71% | -71% | — | +6,969% | -0.51 | 2.58 | 1.86 | 0.99 | -0.76 | 2.58 | 88.37% | -384.34% | -366.62% | -234.19% | 108.03% | -53.02% | 0.52 | -7.67 | 2.60 | 2.47 | 0.93 | 6629.00% | -5964.00% | 6789.00% | -168.89% | -1.45 | 88.18% | 0.00% | 0.00% | 114.12% | 0.75 | 0.92 | -2.88 | -3.86 |
| STTK | Shattuck Labs, Inc. | $3.92 | 187.78M | +1,035% | -87% | — | — | -0.83 | 0.78 | 10.91 | 0.09 | — | 0.78 | 100.00% | -1408.27% | -1318.13% | -67.23% | -568.84% | -60.18% | 0.04 | — | 8.88 | 8.19 | 0.70 | -2732.00% | 24526.00% | -2580.00% | -97.02% | -6.79 | -427.68% | 0.00% | 0.00% | 0.00% | 0.09 | 0.12 | -1.25 | -4.52 |
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
- CEO
- Anhco Nguyen
- Employees
- 153
- Beta
- -0.42
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2.76 ÷ $4.90) − 1 = -43.67% (DCF, example).